S38 Digital oral presentations hoc exploratory analysis investigated the effect of VDZ treatment on existing and new EIMs in patients with CD enrolled in GEMINI 2 (NCT00783692). Methods: Data were collected on 5 categories of EIM and assessed using the following definitions: sustained resolution (absence of an EIM symptom, sustained to study end), worsening of existing EIM and occurrence of new EIM. For the category of arthritis/arthralgia (ar/ar), Kaplan-Meier (KM) estimates were used to describe "time to sustained resolution". A multivariate Cox regression adjusting for potential baseline confounding factors was conducted. In patients receiving corticosteroids (CS), the influence of steroid tapering on the occurrence of new or worsening ar/ar was explored, with prednisone equivalent dose (≤30 mg) as a time-dependent covariate. Results: Patients (pts) received VDZ (n=814), VDZ/placebo (VDZ/PLA; VDZ to Week 6, PLA Week 6-52; n=153) or PLA only (n=148). Baseline EIM incidence was similar across treatment groups (Table). Further analyses focussed on ar/ar as the most common EIM. Predicted annual rates of sustained resolution of ar/ar were 51% (VDZ), 41% (VDZ/PLA) and 36% (PLA; Figure). VDZ pts were 32% more likely to achieve sustained resolution of ar/ar versus PLA (not significant [NS], Table) and 21% less likely to have a wors-ening/new occurrence (NS, Table). In pts receiving CS (n=530), adjustment for CS withdrawal resulted in ∼4% increased likelihood of new or worsening ar/ar in all groups over time (30 mg dose reduction HR 1.04 [95% CI: 0.67-1.60], NS). Hazard reduction for the VDZ groups versus those on PLA was similar (VDZ, 0.73 [95% CI: 0.44-1.22], NS; VDZ/PLA, 0.72 [95% CI: 0.37-1.39], NS). Conclusions: In this post hoc exploratory analysis there was a trend for both reduced incidence of new or worsening ar/ar and increased rates of sustained resolution of ar/ar in pts receiving VDZ. CS tapering increased the probability of ar/ar in all groups. GEMINI 2 was not sufficiently powered to assess worsening/new occurrences of other EIMs.
CITATION STYLE
Yarur, A., Bruss, A., Jain, A., Kondragunta2, V., Hester, K., Luna, T., … Stein, D. (2017). DOP020 Higher vedolizumab levels are associated with deep remission in patients with Crohn’s disease and ulcerative colitis on maintenance therapy with vedolizumab. Journal of Crohn’s and Colitis, 11(suppl_1), S38–S38. https://doi.org/10.1093/ecco-jcc/jjx002.057
Mendeley helps you to discover research relevant for your work.